NEUROPACE, INC. Selling and Marketing Expense
NEUROPACE, INC. (NPCE) reported Selling and Marketing Expense of $12.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-11
- NEUROPACE, INC. selling and marketing expense for the quarter ending 2026-06-30 was $12.12M, a 5.53% increase year-over-year.
- NEUROPACE, INC. selling and marketing expense for the quarter ending 2026-03-31 was $11.58M, a 5.27% increase year-over-year.
- NEUROPACE, INC. selling and marketing expense for the quarter ending 2025-12-31 was $10.94M, a 9.90% increase year-over-year.
- NEUROPACE, INC. selling and marketing expense for the quarter ending 2025-09-30 was $12.60M, a 26.88% increase year-over-year.
- NEUROPACE, INC. selling and marketing expense for fiscal 2025 was $46.58M, a 17.42% increase from fiscal 2024.
- NEUROPACE, INC. selling and marketing expense for fiscal 2024 was $39.67M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12.12M 10-Q · filed 2026-08-11 | $23.71M 10-Q · filed 2026-08-11 | $34.64M derived: sum of 3 quarters · filed 2026-08-11 | $47.24M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $11.58M 10-Q · filed 2026-05-12 | $22.52M derived: sum of 2 quarters · filed 2026-05-12 | $35.12M derived: sum of 3 quarters · filed 2026-05-12 | $46.61M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $23.53M derived: sum of 2 quarters · filed 2026-03-03 | $35.02M derived: sum of 3 quarters · filed 2026-08-11 | $46.58M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $12.60M 10-Q · filed 2025-11-04 | $24.09M derived: sum of 2 quarters · filed 2026-08-11 | $35.64M 10-Q · filed 2025-11-04 | $45.04M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $11.49M 10-Q · filed 2026-08-11 | $12.04M 10-Q · filed 2025-08-12 | $21.89M 10-Q · filed 2026-08-11 | $23.05M 10-Q · filed 2025-08-12 | $32.44M derived: sum of 3 quarters · filed 2026-08-11 | $42.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $11.00M 10-Q · filed 2026-05-12 | $20.95M derived: sum of 2 quarters · filed 2026-05-12 | $30.88M derived: sum of 3 quarters · filed 2026-05-12 | $40.64M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $19.88M derived: sum of 2 quarters · filed 2026-03-03 | $29.64M derived: sum of 3 quarters · filed 2026-03-03 | $39.67M 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $9.93M 10-Q · filed 2025-11-04 | $19.68M derived: sum of 2 quarters · filed 2025-11-04 | $29.72M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $9.76M 10-Q · filed 2025-08-12 | $19.79M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |